Monoclonal antibodies that recognise the C‐terminus of PTX3 and disrupt the interaction between PTX3 and CD44 were developed to validate the PTX3/CD44 axis‐induced protumour effects on cancer development, metastasis/invasion and stemness. The gene discussed is CD44; the disease is cancer.